NCT01640912View on ClinicalTrials.gov

Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

May 31, 2014

Conditions
CicatrixScar Prevention
Interventions
DRUG

RXI-109

Single intradermal injection of RXI-109 at incision sites

DRUG

Placebo

Single intradermal injection of placebo at incision sites

Trial Locations (1)

63141

St Louis

All Listed Sponsors
lead

RXi Pharmaceuticals, Corp.

INDUSTRY

NCT01640912 - Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109 | Biotech Hunter | Biotech Hunter